

Bone, Blood, or Liver Tissue

MultiCell Technologies, Inc.

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

Phone: 401-762-0045

FAX: 401-762-0098

E-mail: info@multicelltech.com

Web site: <http://www.multicelltech.com>

OTC BB: MCET

1. Senior Management

W. Gerald Newmin, CFO / CEO

2. Corporate Mission

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. MultiCell's drug development program is focused on the modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications and the production of therapeutic proteins, and is the leading producer of the immortalized human hepatocyte cell lines used by the pharmaceutical industry to develop new drugs and therapeutics.

3. Research/Technology Overview

MultiCell leverages patented technology and expertise to develop therapeutics to treat serious diseases including multiple sclerosis, type-1 diabetes, and infectious disease. The Company's novel technologies have been shown to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system. MultiCell has focused its technologies on four disease targets: multiple sclerosis (MS); type-1 diabetes; and infectious disease. The Company's therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapse-remitting MS; MCT-275, for the treatment of type-1 diabetes; and MCT-465, addressing influenza A infection. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery and for the production of therapeutic proteins.

4. Financial Information Link

Visit http://www.multicelltech.com/investor_relations.html

5. Corporate News Link

Major news since October 2008: In March 2009, MultiCell Technologies announced that it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer. Visit <http://www.multicelltech.com/newsroom.html>

6. Clinical Trials

N/A.